

ARTICLE NAVIGATION

POSTER SPOTLIGHT ABSTRACTS | JUNE 13 2025

Abstract PS18-01: Spatial Transcriptomics-Derived Classification of Invasive Lobular Carcinoma: Associations with Clinical, Genomic Characteristics, and Prognosis FREE

Matteo Serra; Mattia Rediti; Laetitia Collet; Frederic Lifrange; David Venet; Nicola Occelli; Delphine Vincent; Ghizlane Rouas; Denis Larsimont; Miikka Vikkula; Francois P Duhoux; Françoise Rothé; Christos Sotiriou



+ [Author & Article Information](#)
Clin Cancer Res (2025) 31 (12_Supplement): PS18-01.
<https://doi.org/10.1158/1557-3265.SABCS24-PS18-01>

 Split-Screen

 Share ▾

 Tools ▾

 Versions ▾

Abstract

Background: Invasive lobular carcinoma (ILC) is the second most prevalent histological subtype of breast cancer. This study presents four newly identified ILC subtypes associated with tumor microenvironment (TME) heterogeneity and examines their associations with clinical characteristics and prognosis. Methods: Spatial transcriptomics (ST, Visium 10X) was performed on frozen tumor samples from 43 primary hormone receptor positive (HR+), HER2-negative (HER2-) ILCs. H&E slides were morphologically annotated, and ST spots were clustered by gene expression. By integrating morphology and sequencing data, ILCs were classified based on TME heterogeneity using the intNMF algorithm. Subtypes were annotated using morphology (image analysis), pathway enrichment analysis (GSEA), and cell type composition from single-cell deconvolution (CARD software). Gene signatures for each subtype were derived and used to retrieve the subtypes in METABRIC (ILC cohort, n = 122) and SCAN-B (ILC cohort, n = 853) microarray/bulk RNA-sequencing datasets. Statistical analyses included chi-square and Kruskal-Wallis tests to investigate associations with clinical characteristics and Cox proportional hazard models for univariate and multivariate survival analyses in both METABRIC and SCAN-B. Results: Patient-level classification revealed four ILC subtypes, namely proliferative (P), normal-stroma enriched (NSE), metabolic (M), and metabolic-immune enriched (MIE). In our ST cohort, the P subtype (n = 12) was enriched in tumor cells and proliferation-related pathways; NSE subtype (n = 10) was associated with more fibroblasts, carcinoma in situ, and heightened expression of EMT-related pathways; the M subtype (n = 9) was enriched in endothelial cells, and heightened AR gene expression; the MIE subtype (n = 10) was enriched in endothelial cells, M2 macrophages, and metabolic-related pathways. All four subtypes were identified in METABRIC (NSE = 40, P = 34, MIE = 17, M = 31) and SCAN-B (NSE = 291, P = 226, MIE = 150, M = 186), with GSEA showing consistent differences at the

Search Institution
Library



gene expression level. In METABRIC, the P and MIE subtypes were associated with high and low cellularity, respectively ($p = 0.042$), and P was also linked to higher tumor grade ($p = 0.0187$). Notably, the P subtype exhibited more copy number aberrations (CNA) compared to other subtypes ($p = 0.0159$), but no differences in tumor mutational burden. In SCAN-B, the P and NSE subtypes were associated with larger and smaller tumors, respectively ($p < 0.001$). The P subtype was also linked to higher tumor grade ($p < 0.001$), lymph node involvement ($p = 0.02$), and high Ki67 ($p < 0.001$). In METABRIC, univariate analysis showed NSE and P subtypes to be associated with good and poor prognosis, respectively, for relapse-free interval (RFI) (HR = 0.56, $p = 0.027$, FDR = 0.055; HR = 1.8, $p = 0.019$, FDR = 0.055). Multivariable analysis confirmed NSE's association with good prognosis (HR = 0.47, $p = 0.03$, FDR = 0.12 for RFI), even when correcting for clinical features. In SCAN-B, univariate analysis revealed an association between NSE and longer RFI (HR = 0.42, $p = 0.0018$, FDR = 0.0035) and between P and shorter RFI (HR = 2.2, $p = 0.0014$, FDR = 0.0035). When correcting for clinical characteristics, NSE remained associated with longer RFI (HR = 0.54, $p = 0.035$, FDR = 0.11), while a trend was observed for P and shorter RFI (HR = 1.6, $p = 0.079$, FDR = 0.13). Conclusions: Spatial transcriptomics revealed four ILC subtypes describing TME heterogeneity. These subtypes were successfully identified in microarray/bulk-RNA sequencing datasets and associated with different clinical characteristics. Importantly, the subtypes showed differences in disease outcomes, refining prognosis in ILC.

Citation Format: Matteo Serra, Mattia Rediti, Laetitia Collet, Frederic Lifrange, David Venet, Nicola Occelli, Delphine Vincent, Ghizlane Rouas, Denis Larsimont, Miikka Vikkula, Francois P Duhoux, Françoise Rothé, Christos Sotiriou. Spatial Transcriptomics-Derived Classification of Invasive Lobular Carcinoma: Associations with Clinical, Genomic Characteristics, and Prognosis [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr PS18-01.

©2025 American Association for Cancer Research

[View Metrics](#)

Citing Articles Via

Google Scholar

[Skip to Main Content](#)

Advertisement



Email Alerts

- Article Activity Alert
- Online First Alert
- eTOC Alert
- Editors' Picks Alert

Latest	Most Read	Most Cited
Therapeutic Targeting of Epithelial–Mesenchymal Cellular Plasticity in Pancreatic Cancer PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study		

[Skip to Main Content](#)

Online ISSN 1557-3265

Print ISSN 1078-0432

AACR Journals

- Blood Cancer
Discovery
Cancer Discovery

Cancer
Epidemiology,
Biomarkers &
Prevention
Cancer Immunology
Research
Cancer Prevention
Research

Cancer Research
Cancer Research
Communications
Clinical Cancer
Research
Molecular Cancer
Research
Molecular Cancer
Therapeutics



Resources

- Information on Advertising & Reprints

Information for Institutions/Librarians

RSS Feeds

Privacy Policy

AACR Journals
on Social Media



Copyright © 2025 by the American Association for Cancer Research.